Abstract: The present invention relates to methods and pharmaceutical compositions for treating conditions in non-human mammals, including seizures, idiopathic epilepsy, anxiety, noise aversion, and separation anxiety. The treatment involves administering cannabinoid compositions comprising at least one cannabinoid selected from cannabidiol (CBD), cannabidivarin (CBDV), cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), and tetrahydrocannabivarin (THCV). Specific embodiments comprise CBD isolate nano-particles with purity greater than 99% of total cannabinoids and particle sizes less than 100 nanometers, suspended in oil-based media, essentially free of tetrahydrocannabinol (THC). Methods include acute treatment for noise aversion administered immediately prior to or during noise events, and daily administration for separation anxiety management. A pharmaceutical composition comprising CBD, CBDV, and CBC in a 5:1:1 weight ratio for treating seizures and idiopathic epilepsy is disclosed.